Experimental study on shock tube flows for the application of needle-free drug delivery

2014 ◽  
Author(s):  
Guang Zhang ◽  
Jinouk Park ◽  
Heuy Dong Kim ◽  
Gyuwan Kim
Keyword(s):  
Drug Delivery ◽  
Experimental Study ◽  
Shock Tube ◽  
Free Drug

scholarly journals Experimental Study of Unsteady Flow in a Shock Tube for Needle-Free Drug Delivery

2015 ◽  
Vol 105 ◽  
pp. 241-249 ◽  
Author(s):  
Guang Zhang ◽  
Yun Sung Kim ◽  
Gyu Wan Kim ◽  
Toshiaki Setoguchi ◽  
Heuy Dong Kim
Keyword(s):  
Drug Delivery ◽  
Experimental Study ◽  
Unsteady Flow ◽  
Shock Tube ◽  
Free Drug

scholarly journals Factors Contributing to Increased Blast Overpressure Inside Modern Ballistic Helmets

2020 ◽  
Vol 10 (20) ◽  
pp. 7193
Author(s):  
Maciej Skotak ◽  
Jonathan Salib ◽  
Anthony Misistia ◽  
Arturo Cardenas ◽  
Eren Alay ◽  
...  
Keyword(s):  
Experimental Study ◽  
Shock Tube ◽  
Principle Component Analysis ◽  
Hot Spots ◽  
Shape Factor ◽  
Elevated Pressure ◽  
Focal Points ◽  
Parietal Region ◽  
Blast Overpressure ◽  
Pressure Fields

This study demonstrates the orientation and the "shape factor" have pronounced effects on the development of the localized pressure fields inside of the helmet. We used anatomically accurate headform to evaluate four modern combat helmets under blast loading conditions in the shock tube. The Advanced Combat Helmet (ACH) is used to capture the effect of the orientation on pressure under the helmet. The three modern combat helmets: Enhanced Combat Helmet (ECH), Ops-Core, and Airframe, were tested in frontal orientation to determine the effect of helmet geometry. Using the unhelmeted headform data as a reference, we characterized pressure distribution inside each helmet and identified pressure focal points. The nature of these localized “hot spots” is different than the elevated pressure in the parietal region of the headform under the helmet widely recognized as the under-wash effect also observed in our tests. It is the first experimental study which indicates that the helmet presence increased the pressure experienced by the eyes and the forehead (glabella). Pressure fingerprinting using an array of sensors combined with the application of principle component analysis (PCA) helped elucidate the subtle differences between helmets.

Preclinical Development Of a Nanomedicne Approach For Multiple Myeloma Targeting The Myc Oncoprotein

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4228-4228
Author(s):  
Deepti Soodgupta ◽  
Dipanjan Pan ◽  
Grace Hu ◽  
Angana Senpan ◽  
Xiaoxia Yang ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Drug Delivery ◽  
Multiple Myeloma ◽  
Flow Cytometry ◽  
Conflicts Of Interest ◽  
Annexin V ◽  
Free Drug ◽  
Preclinical Development ◽  
Late Antigen ◽  
Mtt Assays

Abstract Purpose This study investigated alpha 4 beta 1/ Very Late Antigen-4 (α4β1/ VLA-4)-integrin targeted nanotherapy approach to deliver a new lipase-labile prodrug. Experimental Design A phospholipid-based MYC-MAX inhibitor prodrug (MI1-PD) was synthesized, and its inherent anti-proliferate potency was compared to the lipid-free compound (MI1) using mouse multiple myeloma (MM) cell line (5TGM1). VLA-4-targeted perfluorocarbon (PFC) nanoparticles binding to 5TGM1 cells was measured and compared to biomarker expression assessed with flow cytometry using antibodies. The efficacy of MI1-PD incorporated into non-targeted and VLA-4-targeted PFC NP exposed to 5TGM1 cells was assessed with MTT assays, Annexin V and cell cycle analysis. Results MI1-PD was more potent by several orders of magnitude than its free drug counterpart in culture. Targeted NP binding correlated well with biomarker expression assessment by flow cytometry in 5TGM1 cells. Non-targeted NPs had no appreciable binding to 5TGM1 cells. High anti-MM potency of MI1-PD was noted in VLA-4-targeted NPs compared to the non-targeted NPs demonstrating that the efficacy was dependent on expression of the targeted biomarker to afford particle-to-cell drug delivery. Conclusions These results suggest the feasibility of an improved integrin VLA-4- targeted nanotherapy approach to deliver a lipase- labile prodrug construct, MI1-PD. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document